Seeking Alpha

Somaxon Pharmaceuticals, Inc. (SOMX)

SOMX is defunct.
  • Dec. 17, 2012, 4:51 PM
    Somaxon Pharmaceuticals (SOMX) says that its licensee Paladin Labs has received approval from Health Canada for its New Drug Submission for its insomnia treatment Silenor. The drug's launch is expected to around mid-2013. Shares +1% AH.
    | Comment!
  • Dec. 11, 2012, 12:45 PM
    Midday top 10 gainers: BGMD +146%. SOMX +75%. ACUR +56%. TNS +43%. ULBI +18%. MEAD +16%. ESYS +15%. SZYM +14%. GTXI +13%. CLWR +12%.
    Midday top 10 Losers: CBMX -11%. ESIO -11%. AMCN -9%. SEV -9%. GGAL -8%. SPW -8%. TELK -7%. [[JW-A]] -7%. MGLN -7%. SXC -7%.
  • Dec. 11, 2012, 9:10 AM
    Somaxon Pharmaceuticals (SOMX) +103.4% premarket after agreeing to be acquired by Pernix Therapeutics (PTX) in a stock-for-stock transaction valued at $25M.
    | Comment!
  • Dec. 11, 2012, 9:10 AM
    Premarket gainers: SOMX +101%. TNS +45%. VE +6%. CLDX +5%. URBN +5%.
    Losers: ESIO -19%.
    | Comment!
  • Jul. 20, 2012, 10:38 AM
    Somaxon Pharmaceuticals (SOMX -19%) gets smacked after saying its selling approximately 9.4M shares of its common stock and warrants in a registered direct offering to purchase up to approximately 4.7M shares of its common stock to institutional investors at $0.32 per share and per warrant. Aggregate proceeds from the transaction will total approximately $3.0M.
    | Comment!
  • Jul. 18, 2012, 11:43 AM
    Somaxon (SOMX +83%) soars this morning - after initially surging over 150% in pre-open trading - on the back of yesterday's announcement of its litigation settlement over Silenor with Mylan (MYL +0.8%) and Par Pharmaceuticals. The company added that it sees higher Q2 net sales for Silenor, now seeing revenue of approximately $2.8M to $2.9M, up from reported sales of $2.7M in Q1.
    | Comment!
  • Oct. 3, 2011, 4:50 PM
    Somaxon Pharmaceuticals (SOMX) jumps in post-trade after saying it had a productive meeting with the FDA relating to the over-the-counter development program for its insomnia drug Silenor, developed jointly with Procter & Gamble (PG). SOMX +22.5% AH.
    | Comment!
Visit Seeking Alpha's
Company Description
We are a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. We submitted our NDA for Silenor®... More